AOBiome Therapeutics’ topical biotherapeutic B244 demonstrated positive Phase 2b results from its 547 patient trial for both Pruritus (Itch) and Appearance in its 547 patient Phase 2b trial of Atopic Dermatitis (Eczema)
CAMBRIDGE, Mass., Feb. 22, 2022 /PRNewswire/ -- AOBiome Therapeutics, a clinical stage biotechnology company focused on transforming human health by developing...